Dr. Sachin Jadhav: Shaping The Landscape Of Cancer Treatment & Bone Marrow Transplantation
Dr. Sachin Jadhav
CEO
Dr. Sachin Jadhav, the Founder, CEO, and Managing Director of Chiron Cancer Care, stands as a notable leader in these fields. With his clinical educational background encompassing MBBS, MD, DM (Clinical Hematology), and a Fellowship in Leukemia/BMT, he brings a wealth of knowledge to his role as a doctor. Parallely, Dr. Sachin has played a pivotal role in the healthcare landscape, serving as the Head of Hematology and BMT in various hospital chains. His leadership focuses on creating high-performing teams that provide international quality clinical outcomes and thus create robust and sustainable Clinical Programs.
With his own venture, Chiron Cancer Care, he is building centers to improve access to high-quality care in Oncology and Bone Marrow Transplantation. Let’s hear more from him.
"My approach is collaborative, emphasizing teamwork, cultivating a positive work culture, & establishing effective processes to ensure favorable clinical & business outcomes in our treatments"
Could you provide some insights into your professional background and experi-ences? Additionally, what drives your daily routine?
My background lies in Hematology and bone marrow transplantation as a physician, specifically dealing with blood-related issues. This encompasses a range, from minor concerns like low hemoglobin or platelet counts to more complex cases such as blood cancers. My specialization extends to treating blood cancers and performing bone marrow transplants for eligible patients. Following my basic education in India, I spent about one and a half years studying in Canada and London, driven by two main objectives- first, to gain diverse training experiences, and second, to understand effective leadership approaches in contrast to the authoritative style often seen in our country's medical training.
In the West, I observed a collaborative approach to achieving excellent results, emphasizing teamwork and systematic processes rather than hierarchical dominance. This contrasted with the master slave dynamic prevalent in our medical training, which I found unsavory. My goal was to bring back these best practices to enhance the treatment of hematology patients in India. In 2013, I returned to India, embarking on my professional journey at Global Hospital in Bangalore. Here, I established the Department of Hematology and Bone Marrow Transplant, realizing the need to build effective teams and implement quality management.
How do you utilize health information technologies for healthcare decision-making and investigations? Additionally, could you share information on the hospital's latest tools deployed for both investigations and treatment?
We employ information technology to esta-blish connectivity across our centers, creating a unified platform to ensure consistent and high-quality patient treatment throughout our network. This technology aids us in quality management, enabling an assessment of our clinical outcomes and ensuring the achievement of desired results. It serves as a valuable tool for training healthcare profes-sionals, including doctors and nurses, and contributes to our overall quality management efforts, seamlessly integrating information technology into our daily operations.
Regarding investigations and treatments, we focus on two main fronts. First, we strive to provide standardized treatment by formulating policies and protocols, with an emphasis on cost reduction given our origin in low and middle-income countries. Secondly, we prioritize access to next-generation diagnostics and medications. An example would be the research that we collaborated on with Bionano laboratories in San Diego, US, involving a new genomic test known as Optical Genome Mapping or OGM.
We aim to introduce this advanced genomic test for cancer patients in India. Furthermore, we have procured novel therapeutics valued at approximately five crores over the past four years, most of which were obtained at no cost. These medications, currently unavailable in India, represent our commitment to bringing in innovative diagnostic and treatment modalities and assessing their impact on clinical outcomes in our country.
How do you view the sentiment within the industry? Are there expectations of increased investor participation to support further development? What is your take on this?
It's exciting to witness a significant influx of investments and ongoing consolidation in the healthcare sector. However, the pace at which investors aim to exit creates pressure for organizations to prioritize top and bottomline considerations over long-term sustain-ability. We emphasize the importance of addressing two crucial aspects, which I may sound repetitive about, but they are essential – clinical outcomes and affordability.
By focusing on these, we can establish a foundation for a sustainable business model that delivers high-quality patient care. While it's necessary to analyze profit and loss statements and spread sheets, doing so in isolation without considering the patient's well-being may compromise the industry's integrity, even in the medium term.
Could you provide more details on what measures can scholars or companies under take to extend the availability of the best treatments for individuals dealing with blood
We employ information technology to esta-blish connectivity across our centers, creating a unified platform to ensure consistent and high-quality patient treatment throughout our network. This technology aids us in quality management, enabling an assessment of our clinical outcomes and ensuring the achievement of desired results. It serves as a valuable tool for training healthcare profes-sionals, including doctors and nurses, and contributes to our overall quality management efforts, seamlessly integrating information technology into our daily operations.
Over the past 11 years, we've set up a total of 14 centers, & in the next three months, three additional bone marrow transplant centers will be added within the Gem Care Network, bringing the total to 17
Regarding investigations and treatments, we focus on two main fronts. First, we strive to provide standardized treatment by formulating policies and protocols, with an emphasis on cost reduction given our origin in low and middle-income countries. Secondly, we prioritize access to next-generation diagnostics and medications. An example would be the research that we collaborated on with Bionano laboratories in San Diego, US, involving a new genomic test known as Optical Genome Mapping or OGM.
We aim to introduce this advanced genomic test for cancer patients in India. Furthermore, we have procured novel therapeutics valued at approximately five crores over the past four years, most of which were obtained at no cost. These medications, currently unavailable in India, represent our commitment to bringing in innovative diagnostic and treatment modalities and assessing their impact on clinical outcomes in our country.
How do you view the sentiment within the industry? Are there expectations of increased investor participation to support further development? What is your take on this?
It's exciting to witness a significant influx of investments and ongoing consolidation in the healthcare sector. However, the pace at which investors aim to exit creates pressure for organizations to prioritize top and bottomline considerations over long-term sustain-ability. We emphasize the importance of addressing two crucial aspects, which I may sound repetitive about, but they are essential – clinical outcomes and affordability.
By focusing on these, we can establish a foundation for a sustainable business model that delivers high-quality patient care. While it's necessary to analyze profit and loss statements and spread sheets, doing so in isolation without considering the patient's well-being may compromise the industry's integrity, even in the medium term.
Could you provide more details on what measures can scholars or companies under take to extend the availability of the best treatments for individuals dealing with blood
-related diseases or disorders?
Unfortunately, access to high-quality and affordable treatment remains a challenge for the majority of patients in India and other developing nations like Bangladesh, Sri Lanka, Kenya, and Tanzania. Our commitment has been to establish as many treatment centers as possible, ensuring that patients receive excellent care at reasonable costs. Over the past 11 years, we've set up a total of 14 centers, and in the next three months, three additional bone marrow transplant centers will be added within the Gem Care Network, bringing the total to 17. This expansion is part of our ongoing efforts to enhance accessibility to treatment.
Could you elaborate on the distinctive characteristics of your leadership style? Additionally, what principles or appro-aches guide your leadership of the team?
I have undergone leadership training at Harvard Business School and engaged in extensive reading to shape my leadership style. My approach is collaborative, emphasizing teamwork, cultivating a positive work culture, and establishing effective processes to ensure favorable clinical and business outcomes in our treatments.
The leadership style is not only colla-borative but also motivational, aiming for a long-term perspective. Our focus is on transforming healthcare delivery in our region, with a primary goal of curing as many individuals as possible. This reflects my choice of leadership that centers around collaboration, motivation and a dedicated commitment to improving healthcare practices in our community.
What is the envisioned roadmap for the next five years?
I've established 14 hematology bone marrow transplant centers and five smaller cancer centers. Chiron and Gem Care have plans to expand and create at least 20-30 more Centers for Oncology and Bone Marrow Transplantation within the next five to ten years.
The goal is to create centers where the entire healthcare team, including doctors and nurses, finds value and pride in their work. The vision includes generating employment opportunities that foster scientific, intellectual, and professional growth for everyone involved, ultimately contributing to saving more lives.
Before retirement, a focus on advancing scientific knowledge is crucial. The organization is actively involved in research, particularly in cancer genomics and bone marrow transplant complications, with the aim of advancing these fields within the country and addressing region-specific challenges, such as prevalent infections. These goals encompass both healthcare delivery and research aspects.
Dr. Sachin Jadhav, CEO, Chiron
Dr. Sachin Jadhav is an accomplished healthcare leader. He holds degrees in MBBS, MD, and DM (Clinical Hematology). As Program Director for several hospital chains, he has created 14 Bone Marrow Transplant Centers. His collaborative leadership and commitment to research have shaped his work. His venture Chiron Cancer Care fosters a patient-centric, team driven, and technology-enabled healthcare model for sustainable value creation for patients, healthcare providers, and the industry.
Unfortunately, access to high-quality and affordable treatment remains a challenge for the majority of patients in India and other developing nations like Bangladesh, Sri Lanka, Kenya, and Tanzania. Our commitment has been to establish as many treatment centers as possible, ensuring that patients receive excellent care at reasonable costs. Over the past 11 years, we've set up a total of 14 centers, and in the next three months, three additional bone marrow transplant centers will be added within the Gem Care Network, bringing the total to 17. This expansion is part of our ongoing efforts to enhance accessibility to treatment.
Could you elaborate on the distinctive characteristics of your leadership style? Additionally, what principles or appro-aches guide your leadership of the team?
I have undergone leadership training at Harvard Business School and engaged in extensive reading to shape my leadership style. My approach is collaborative, emphasizing teamwork, cultivating a positive work culture, and establishing effective processes to ensure favorable clinical and business outcomes in our treatments.
The leadership style is not only colla-borative but also motivational, aiming for a long-term perspective. Our focus is on transforming healthcare delivery in our region, with a primary goal of curing as many individuals as possible. This reflects my choice of leadership that centers around collaboration, motivation and a dedicated commitment to improving healthcare practices in our community.
What is the envisioned roadmap for the next five years?
I've established 14 hematology bone marrow transplant centers and five smaller cancer centers. Chiron and Gem Care have plans to expand and create at least 20-30 more Centers for Oncology and Bone Marrow Transplantation within the next five to ten years.
The goal is to create centers where the entire healthcare team, including doctors and nurses, finds value and pride in their work. The vision includes generating employment opportunities that foster scientific, intellectual, and professional growth for everyone involved, ultimately contributing to saving more lives.
Before retirement, a focus on advancing scientific knowledge is crucial. The organization is actively involved in research, particularly in cancer genomics and bone marrow transplant complications, with the aim of advancing these fields within the country and addressing region-specific challenges, such as prevalent infections. These goals encompass both healthcare delivery and research aspects.
Dr. Sachin Jadhav, CEO, Chiron
Dr. Sachin Jadhav is an accomplished healthcare leader. He holds degrees in MBBS, MD, and DM (Clinical Hematology). As Program Director for several hospital chains, he has created 14 Bone Marrow Transplant Centers. His collaborative leadership and commitment to research have shaped his work. His venture Chiron Cancer Care fosters a patient-centric, team driven, and technology-enabled healthcare model for sustainable value creation for patients, healthcare providers, and the industry.